Correction: Predicting Tumor Responses to Gefitinib and Erlotinib

Ítems similars

• Predicting Tumor Responses to Gefitinib and Erlotinib
  Publicat: (2005)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  per: Nishino, Mizuki, et al.
  Publicat: (2016)
• Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells
  per: Bachawal, Sunitha V, et al.
  Publicat: (2010)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  per: Zakowski, Maureen F., et al.
  Publicat: (2009)
• Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
  per: Kim, Hoon-Kyo, et al.
  Publicat: (2007)